… controlled trial (RCT) found that pravastatin treatment for … GRAMplusC4D).33 For drug target genes significantly … modifying medications, including statins, fenofibrate, evinacumab, mipomersen, and anacetrapib, … in how different doctors or healthcare institutions …

… high-dose statin therapy, new lipid-lowering drugs such as … Mongolian medicine with proven clinical application for treatment of … were purchased from Nanjing Jiancheng Biotech Co., Ltd (Nanjing, … et al. Effects of anacetrapib in patients with atherosclerotic …

… Statin Therapy (ROSE) clinical trial in the peer-reviewed journal, Nature Medicine … compared to placebo, treatment with obicetrapib led to … CETP inhibition observed with anacetrapib and evacetrapib. A … ’s ongoing clinical trials, particularly as they …

… the practice of medicine. Before the availability of statins, no one … REVEAL, a combination of anacetrapib and atorvastatin was shown to … FDA in 2015. However, despite the extraordinary efficacy of these drugs … . After all, taking a pill once-a-day is far …

… fact, in early clinical trials, these drugs totally remodeled a heart patient … anacetrapib/atorvastatin vs. atorvastatin and demonstrated that the CETPi/statin … billion 30,000 patient outcomes trial. The FDA has required other companies …

… through counselling and medicines as per their condition … anacetrapib by Merck, and a new LDL lowering drug … company lost its hyperlipidemia treatment drug patent in early 2016 … FDA gave its approval to Watson Pharmaceuticals Inc. to launch a generic drug …

… ; cholesterol HDL. Outcomes from clinical trials of CETP inhibitors, however, have … participants in the CETP inhibitor trials were obese, Lin Zhu, MD … , they studied the effects of anacetrapib, a CETP inhibitor, in transgenic …

… , one doesn’t enter pharmaceutical R&D if he … experimental medicines that enter human trials actually results in an FDA approval … LDL-cholesterol on top of statins. Some even dreamed that … to market. Merck’s entrant, anacetrapib, got the furthest. Merck …

… by Parsippany, NJ-based Medicines Co. (NASDAQ: MDCO) … trial along with partner Alnylam Pharmaceuticals (NASDAQ: ALNY). The drug … FDA-approved drugs Melinta (NASDAQ: MLNT) is buying are Vabomere, a treatment … . Merck said the anacetrapib trial met its main goal …

… closely watched experimental cholesterol medicine after mediocre test results. … its drug, a so-called CETP inhibitor called anacetrapib, long … August it disclosed the pill only cut those risks … part because cheap, genetic statin drugs lower cholesterol well for …